Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral triamterene disposition.

F Sörgel, J Hasegawa, E T Lin

    Clinical Pharmacology and Therapeutics
    |September 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Black Hole Spectroscopy and Tests of General Relativity with GW250114.

    Physical review letters·2026
    Same author

    GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

    Physical review letters·2025
    Same author

    Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.

    CPT: pharmacometrics & systems pharmacology·2017
    Same author

    [Pharmacokinetics and pharmacodynamics of antibiotics in intensive care].

    Medizinische Klinik, Intensivmedizin und Notfallmedizin·2016
    Same author

    Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

    Antimicrobial agents and chemotherapy·2013
    Same author

    Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

    Antimicrobial agents and chemotherapy·2011

    Triamterene (T) is rapidly metabolized to hydroxytriamterene sulfate (T-O-SO3H), with higher plasma and urine concentrations of the metabolite. Renal clearance of T exceeded its sulfate metabolite, unaffected by hydrochlorothiazide.

    Area of Science:

    • Pharmacokinetics
    • Drug Metabolism
    • Renal Physiology

    Background:

    • Triamterene (T) is a potassium-sparing diuretic.
    • Previous studies identified hydroxytriamterene (T-OH) and its sulfate conjugate (T-O-SO3H) as major metabolites.
    • The precise kinetic profile and interconversion of these metabolites require further elucidation.

    Purpose of the Study:

    • To characterize the pharmacokinetics of triamterene (T) and its metabolites.
    • To quantify the formation and elimination of hydroxytriamterene sulfate (T-O-SO3H).
    • To assess the impact of hydrochlorothiazide coadministration on T disposition.

    Main Methods:

    • High-performance liquid chromatography (HPLC) was employed for quantitative analysis.
    • Plasma and urine samples were analyzed to determine drug and metabolite concentrations.

    Related Experiment Videos

  • Renal clearance of T and its metabolite was calculated.

    • Main Results:

    • Triamterene (T) is rapidly hydroxylated and subsequently conjugated to hydroxytriamterene sulfate (T-O-SO3H).
    • The intermediate T-OH metabolite was undetectable in plasma and urine.
    • Plasma T-O-SO3H concentrations were 7-26 fold higher than T; urine concentrations were 4-13 fold higher.
    • Renal clearance of T (314.5 ml/min) was greater than that of T-O-SO3H (206.1 ml/min).
    • Hydrochlorothiazide did not alter renal clearance of T or T-O-SO3H, despite increasing urine flow and pH.
    • Triamterene bioavailability was lower and more variable from capsules compared to suspension.

    Conclusions:

    • Hydroxylation followed by rapid sulfation is the primary metabolic pathway for triamterene (T).
    • Hydroxytriamterene sulfate (T-O-SO3H) is the predominant circulating and excreted metabolite.
    • Renal excretion of T is more efficient than its sulfate metabolite.
    • Hydrochlorothiazide does not significantly impact triamterene pharmacokinetics or its metabolite's renal clearance.
    • Formulation influences triamterene bioavailability, with suspensions offering better absorption.